Bridging the gap between global healthcare innovation and Malaysian market access.
ARCI Regulatory Consultancy provides expert regulatory strategy, dossier compilation, and submission management, helping pharmaceutical and medical device companies navigate Ministry of Health (MOH) Malaysia requirements with a 98% approval success rate.
ARCI Regulatory Consultancy was founded to solve a critical problem in the Malaysian healthcare market: the complexity of regulatory compliance. What started as a small advisory firm has grown into a premier consultancy trusted by multinational pharmaceutical giants and innovative biotech startups alike.
To accelerate the availability of safe, quality healthcare products in Malaysia by providing scientifically sound and ethically robust regulatory pathways.
Regulatory affairs is not just about filling forms. It’s about strategy, foresight, and relationships.
We use our deep understanding of NPRA workflows to prevent common dossier errors that cause months of delay. We get it right the first time.
We maintain professional, transparent relationships with officers at MOH, NPRA, and MDA, allowing for clear communication on complex files.
Our team includes pharmacists and scientists who understand the molecular and clinical data, not just the regulations.
We don't just register and leave. We manage variations, renewals, and post-market safety reporting for the life of your product.
We specialized in the specific requirements of Malaysia's key regulatory bodies.